Citi Starts Keryx Biopharmaceuticals (KERX) at Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Brean Capital Reiterates Buy on Keryx Biopharma (KERX) on Potential Catalysts and Improving Sales Dynamics
September 4, 2015 9:02 AM EDTBrean Capital reiterated a Buy rating and $22.00 price target on Keryx Biopharmaceuticals (NASDAQ: KERX) on potential catalysts and improving sales dynamics. Keryx's 50% salesforce increase should make a noticeable impact on revenue, on which analyst Jonathan Aschoff says Keryx will be judged more than its bottom line, for the foreseeable future.
Aschoff commented, "We view the recent Keryx selloff as overdone, especially when considering several factors that we believe have led to a... More
